{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T01:23:57Z","timestamp":1781227437050,"version":"3.54.1"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Hypertension is highly prevalent and uncontrolled among hemodialysis patients. In Pakistan published data does not provide enough information about the management and factors associated with uncontrolled hypertension in hemodialysis patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Objective<\/jats:title>\n            <jats:p>This study was conducted to evaluate the factors influencing the pharmacotherapeutic management and control of hypertension in hemodialysis patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A prospective follow-up study was conducted on hemodialysis patients who were enrolled at study sites between 1 June 2020 and 31 December 2020. The predialysis blood pressure (BP) readings were recorded as mean SBP and DBP at baseline and for each of 6\u2005months. Multivariate analyses were applied to analyze the factors associated with uncontrolled hypertension in hemodialysis patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The average predialysis BP (SBP and DBP) of study participants at baseline visit was 158.41 and 87.22\u2005mmHg respectively. After 6\u2005months the study participants have 150.27\u2005mmHg and 80.03\u2005mmHg average predialysis SBP and DBP respectively. Only 28.1% of hemodialysis patients were on target BP after 6\u2005months. Results of multivariate analysis have shown that the use of beta-blockers and calcium channel blockers (CCBs) were significantly associated with hypertension control at baseline [odds ratio (OR)\u2005=\u20051.432, <jats:italic toggle=\"yes\">P<\/jats:italic> value\u2005=\u20050.034] (OR\u2005=\u20051.499, <jats:italic toggle=\"yes\">P<\/jats:italic> value\u2005=\u20050.045) and at after 6\u2005months (OR\u2005=\u20052.824, <jats:italic toggle=\"yes\">P<\/jats:italic> value\u2005=\u20050.015) (OR\u2005=\u20051.883, <jats:italic toggle=\"yes\">P<\/jats:italic> value\u2005=\u20050.032).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>This study revealed that among the antihypertensive drugs, CCBs and beta-blockers provided better management in controlling hypertension among hemodialysis patients.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mbp.0000000000000656","type":"journal-article","created":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T10:00:05Z","timestamp":1688637605000},"page":"253-259","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Evaluation of hypertension control among hemodialysis patients in Pakistan: a prospective follow-up study"],"prefix":"10.1097","volume":"28","author":[{"given":"Kiran","family":"Hameed","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Quaid-i-Azam University, Islamabad, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sampath","family":"Chinnam","sequence":"additional","affiliation":[{"name":"Department of Chemistry, M.S. Ramaiah Institute of Technology (affiliated to Visvesvaraya Technological University, Belgaum), Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khanzada Sheraz","family":"Khan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Quaid-i-Azam University, Islamabad, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saima","family":"Mushtaq","sequence":"additional","affiliation":[{"name":"Department of Healthcare Biotechnology, Atta-ur-Rahman School of Applied Biosciences, National University of Sciences and Technology, Islamabad"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nafees","family":"Ahmad","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Faculty of Pharmacy and Health Sciences, University of Balochistan, Quetta, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ammar Ali Saleh","family":"Jaber","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy & Pharmacotherapeutics, Dubai Pharmacy College for Girls, AlMuhaisanah 1, Al mizhar Dubai, UAE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeeshan","family":"Anwar","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Abdul Wali Khan University, Mardan, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inayat","family":"ur-Rehman","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Abdul Wali Khan University, Mardan, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amjad","family":"Khan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Quaid-i-Azam University, Islamabad, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,7,6]]},"reference":[{"key":"R1-20250620","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1007\/s40267-020-00763-5","article-title":"Evaluation of management and factors associated with hypertension control in hemodialysis patients at a tertiary-care hospital in Pakistan.","volume":"36","author":"Ahmad","year":"2020","journal-title":"Drugs Ther Perspect"},{"key":"R2-20250620","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40545-019-0169-y","article-title":"Hypertension control among euvolemic hypertensive hemodialysis patients in Malaysia: a prospective follow-up study.","volume":"12","author":"Khan","year":"2019","journal-title":"J Pharm Policy Pract"},{"issue":"2 Suppl 1","key":"R3-20250620","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.","volume":"39","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"R4-20250620","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1053\/j.ajkd.2005.02.022","article-title":"Low doses of losartan and trandolapril improve arterial stiffness in hemodialysis patients.","volume":"45","author":"Ichihara","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"R5-20250620","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/j.1526-0968.2004.00142.x","article-title":"Comparison of the effects of angiotensin receptor antagonist, angiotensin converting enzyme inhibitor, and their combination on regression of left ventricular hypertrophy of diabetes type 2 patients on recent onset hemodialysis therapy.","volume":"8","author":"Suzuki","year":"2004","journal-title":"Ther Apher Dial"},{"key":"R6-20250620","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1681\/ASN.V113556","article-title":"Predictors of loss of residual renal function among new dialysis patients.","volume":"11","author":"Moist","year":"2000","journal-title":"J Am Soc Nephrol"},{"key":"R7-20250620","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.2215\/CJN.00870116","article-title":"Pharmacotherapy of hypertension in chronic dialysis patients.","volume":"11","author":"Georgianos","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"R8-20250620","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1093\/ndt\/gfn304","article-title":"Effect of amlodipine on cardiovascular events in hypertensive haemodialysis patients.","volume":"23","author":"Tepel","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"R9-20250620","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/S0735-1097(03)00241-9","article-title":"Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial.","volume":"41","author":"Cice","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"R10-20250620","first-page":"45","article-title":"Status of chronic kidney disease of unknown aetiology in Pakistan 3.","volume":"1","author":"Imtiaz","year":"2020","journal-title":"Communities (CINAC)"},{"issue":"2 Suppl 1","key":"R12-20250620","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.","volume":"39","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"R13-20250620","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0002-9343(03)00366-8","article-title":"Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States.","volume":"115","author":"Agarwal","year":"2003","journal-title":"Am J Med"},{"key":"R14-20250620","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1038\/nrneph.2016.129","article-title":"Epidemiology, diagnosis and management of hypertension among patients on chronic dialysis.","volume":"12","author":"Georgianos","year":"2016","journal-title":"Nat Rev Nephrol"},{"key":"R15-20250620","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1042\/cs1030511","article-title":"Association of calcium channel blockers and mortality in haemodialysis patients.","volume":"103","author":"Tepel","year":"2002","journal-title":"Clin Sci"},{"key":"R16-20250620","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1525-139X.2009.00697.x","article-title":"Antihypertensive agents in hemodialysis patients: a current perspective.","volume":"23","author":"Inrig","year":"2010","journal-title":"Semin Dial"},{"key":"R17-20250620","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1093\/ndt\/gfn304","article-title":"Effect of amlodipine on cardiovascular events in hypertensive haemodialysis patients.","volume":"23","author":"Tepel","year":"2008","journal-title":"Nephrol Dial Transpl"},{"key":"R18-20250620","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1681\/ASN.2014040324","article-title":"\u03b2-Blocker dialyzability and mortality in older patients receiving hemodialysis.","volume":"26","author":"Weir","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"R19-20250620","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.amjmed.2007.11.025","article-title":"Hypertension awareness, treatment, and control in chronic kidney disease.","volume":"121","author":"Sarafidis","year":"2008","journal-title":"Am J Med"},{"key":"R20-20250620","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S0828-282X(06)70291-4","article-title":"Cardioprotective medication use in hemodialysis patients.","volume":"22","author":"Miller","year":"2006","journal-title":"Can J Cardiol"},{"key":"R21-20250620","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1053\/j.ajkd.2013.06.008","article-title":"KDOQI US commentary on the 2012 KDIGO clinical practice guideline for anemia in CKD.","volume":"62","author":"Kliger","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"R22-20250620","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1053\/j.ajkd.2015.07.015","article-title":"KDOQI clinical practice guideline for hemodialysis adequacy: 2015 update.","volume":"66","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"R23-20250620","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2215\/CJN.05080418","article-title":"Association of continuation of loop diuretics at hemodialysis initiation with clinical outcomes.","volume":"14","author":"Sibbel","year":"2019","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Blood Pressure Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MBP.0000000000000656","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T17:03:16Z","timestamp":1750438996000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MBP.0000000000000656"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,6]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/mbp.0000000000000656","relation":{},"ISSN":["1359-5237"],"issn-type":[{"value":"1359-5237","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7,6]]}}}